

## In-vitro Diagnostics (IVD) Reagents Market - Global Outlook & Forecast 2025-2030

Market Report | 2025-05-13 | 354 pages | Arizton Advisory & Intelligence

#### **AVAILABLE LICENSES:**

- Single User License \$4799.00
- Team License \$4999.00
- Enterprisewide \$5999.00

### Report description:

The global IVD reagents market is expected to grow at a CAGR of 3.65% from 2024 to 2030.

MARKET TRENDS & DRIVERS

Rising Significance of Biomarker Discovery & Companion Diagnostics

The expanding importance of biomarker discovery and companion diagnostics is reshaping the IVD reagents market. As personalized medicine continues to advance, the demand for high-quality reagents that enable precise biomarker detection and CDx assays is on the rise. Market players who invest in innovative reagent development, form strategic partnerships, and expand into emerging applications will be well-positioned to capitalize on this growing sector. In a time where precision diagnostics is becoming the gold standard, IVD reagent manufacturers have a critical role to play in shaping the future of healthcare.

Rise of Point-of-Care (POC) Testing

Point-of-care testing is transforming the diagnostic landscape, leading to a surge in demand for high-quality IVD reagents. With the emergence of decentralized, rapid, and personalized healthcare diagnostics, reagent manufacturers have an opportunity to expand their market presence through innovation. The growing demand for POC testing is being met by companies, that are utilizing advanced molecular reagents, multiplex testing solutions, and digital-friendly diagnostic receptacles.

Increasing Demand for Customized Diagnostic Tests & Personalized Medicine

The increasing demand for customized diagnostic tests and personalized medicine is shaping the future of the global IVD reagents market. With advancements in molecular diagnostics, Al-driven testing, and regulatory support for precision medicine, the market is poised for strong growth. Companies that invest in innovation, strategic collaborations, and emerging market expansion will be well-positioned to capitalize on the growing demand for customized IVD solutions.

### Expansion of AI and Automation in Diagnostics

As laboratories and healthcare providers increasingly adopt Al-driven systems, the demand for high-quality, automation-friendly IVD reagents will continue to rise. While ongoing technological advancements and strategic collaborations will drive innovation, positioning Al-powered diagnostics as a cornerstone of the future healthcare landscape. Manufacturers that embrace Al-compatible reagent development will be well-positioned to capitalize on this growing market trend.

Growing Prevalence of Chronic & Infectious Diseases

The increasing prevalence of chronic and infectious diseases is a key driver of the global IVD reagents market. The demand for accurate, fast, and cost-effective diagnostic solutions continues to grow, supported by technological advancements and rising healthcare investments. Specifically in emerging economies and personalized medicine applications. Moving forward, innovation in reagent development will play a crucial role in shaping the future of diagnostic testing.

Growing Awareness & Early Disease Detection

The global IVD reagents market is experiencing robust growth due to rising awareness about early disease detection and preventive healthcare. The increasing prevalence of chronic and infectious diseases, coupled with advancements in diagnostic technologies, is driving demand for high-quality IVD reagents. Government initiatives, home-based testing trends, and rapid innovation in molecular diagnostics are further fueling industry expansion.

Innovations in Reagent Formulations

Advances in molecular reagents, lyophilized formulations, automation-friendly solutions, nanotechnology, and eco-friendly alternatives are enhancing diagnostic accuracy, efficiency, and accessibility. Continued R&D and strategic collaborations will accelerate innovation, shaping the future of the IVD industry. As the demand for high-performance diagnostics continues to rise, the market for advanced IVD reagents is poised for substantial growth in the coming years.

Expanding Healthcare Infrastructure & Investments in R&D

The global IVD reagents market is witnessing robust growth, fueled by expanding healthcare infrastructure and increased investments in R&D. As healthcare systems worldwide focus on early disease detection and precision diagnostics, the demand for innovative and high-quality reagents will continue to rise. Ongoing technological advancements and strategic collaborations will drive further industry expansion, ultimately improving healthcare outcomes on a global scale.

SEGMENTATION INSIGHTS

INSIGHTS BY REAGENT TYPE

The global IVD reagents market is segmented by reagent type into immunochemical reagents, biochemical reagents, and chemical reagents, each playing a crucial role in diagnostic testing. Immunochemical reagents are widely used in immunoassays such as ELISA and chemiluminescence assays to detect antigens, antibodies, hormones, and infectious agents, making them essential for disease diagnosis and monitoring. Biochemical reagents are used in enzymatic and metabolic assays to measure biomarkers like glucose, cholesterol, and liver enzymes, playing a key role in clinical chemistry and metabolic disorder detection. Chemical reagents are primarily used in general laboratory tests and hematology assays, facilitating reactions that help analyze blood components, coagulation factors, and electrolyte levels. With increasing demand for early disease detection, personalized

Scotts International, EU Vat number: PL 6772247784

medicine, and point-of-care diagnostics, all three reagent types are driving industry growth globally, supported by technological advancements and expanding healthcare infrastructure.

Segmentation by Reagent Type

- Immunochemical Reagents
- -□Biochemical Reagents
- Chemical Reagents

#### **INSIGHTS BY TECHNOLOGY**

The global IVD reagents market is segmented by technology into immunoassay & clinical chemistry, molecular diagnostics, hematology, microbiology & cytology, and others, each playing a crucial role in disease detection and monitoring. Immunoassay & clinical chemistry dominate the industry due to its widespread use in hormone testing, infectious disease detection, and chronic disease monitoring. Molecular diagnostics is rapidly growing, driven by advancements in PCR, next-generation sequencing (NGS), and companion diagnostics, particularly in oncology and genetic testing. Hematology reagents are essential for blood analysis, including complete blood counts (CBC) and coagulation tests, which are critical for diagnosing blood disorders and managing treatments. Microbiology & cytology reagents aid in identifying bacterial, viral, and fungal infections through culture-based and rapid antigen tests, while cytology reagents are used in cancer screening, such as Pap smears.

Segmentation by Technology

- Immunoassay & Clinical Chemistry
- -□Molecular Diagnostics
- -□Hematology
- -□Microbiology & Cytology
- -□Others

#### **INSIGHTS BY APPLICATION**

The global IVD reagents market is segmented by application into infectious diseases, diabetes, cardiology, oncology, autoimmune diseases, and others. Infectious diseases dominate the market due to the high prevalence of viral and bacterial infections, including COVID-19, HIV, and tuberculosis, driving demand for rapid and molecular diagnostic reagents. Diabetes testing is a significant segment, fueled by the increasing global burden of diabetes and the need for continuous glucose monitoring. Cardiology diagnostics utilize IVD reagents for detecting biomarkers like troponins and cholesterol levels, aiding in the early diagnosis and management of cardiovascular diseases. Oncology applications are growing rapidly with advancements in molecular diagnostics and biomarker-based testing for personalized cancer treatment. Autoimmune disease diagnostics, including rheumatoid arthritis and lupus testing, rely on immunoassay-based reagents for accurate disease detection. The other categories include neurology, nephrology, and genetic testing applications, further contributing to the expansion of the global IVD reagents market.

Segmentation by Application

- -□Infectious Diseases
- -□Diabetes
- -∏Cardiology
- ☐Oncology
- Autoimmune Diseases
- -∏Others

Scotts International, EU Vat number: PL 6772247784

#### **INSIGHTS BY END-USER**

The global IVD reagents market is segmented by end-users, including standard reference labs, hospital-affiliated labs, clinics, and others, each playing a crucial role in diagnostic testing. Standard reference labs dominate the industry due to their high testing volumes, advanced infrastructure, and capability to conduct specialized and high-complexity diagnostic tests. Hospital-affiliated labs hold a significant share of the IVD reagents market as they provide immediate and integrated diagnostic services for inpatients and emergency cases, ensuring faster treatment decisions. Clinics contribute to industry growth by offering point-of-care and routine diagnostic testing, particularly for chronic disease management and infectious disease screening. The other categories include ambulatory care centers, blood banks, industrial laboratories, physician offices, mobile diagnostic centers, and research & academic institutes, which are expanding due to increasing demand for decentralized and personalized diagnostic solutions.

Segmentation by End-users

- -□Standard Reference Labs
- -∏Hospital-affiliated Labs
- -[Clinics
- -∏Others

#### IVD REAGENTS MARKET GEOGRAPHICAL ANALYSIS

North America holds the largest share of the global IVD reagents market in 2024, accounting for over 38%. The North American IVD reagents market is one of the most advanced and rapidly growing segments in the global healthcare industry. Driven by technological advancements, rising chronic disease prevalence, and increasing demand for rapid and accurate diagnostics, the region holds a significant share of the global market. The U.S. and Canada, with their well-established healthcare infrastructure and strong regulatory frameworks, are key contributors to industry growth. Moreover, the rising prevalence of cancer, diabetes, cardiovascular diseases, and infectious diseases is fueling demand for advanced diagnostic reagents in the region. An aging population requires frequent diagnostic testing for chronic disease management and early disease detection.

Europe is the second-largest market in the global IVD reagents market, driven by strong diagnostic research, widespread adoption of IVD regulations (IVDR), and increased funding for healthcare innovation. Germany, France, Russia, and Italy lead in industry share due to robust laboratory infrastructure and government support for early disease detection. Furthermore, APAC is the fastest-growing market in the global IVD reagents market during the forecast period, driven by rising healthcare investments, increasing prevalence of chronic diseases, and a growing middle-class population. Countries like China, Japan, and India are major contributors due to expanding healthcare access and government initiatives for disease screening. Latin America and the Middle East & Africa are emerging IVD reagents markets with strong potential, driven by rising healthcare investments and the need for improved diagnostics.

## Segmentation by Geography

North America

o∏The U.S.

o∏Canada

-[Europe

 $o \square Germany$ 

o∏France

o∏Russia

o∏Spain

o∏Italy

Scotts International, EU Vat number: PL 6772247784

- o∏The U.K.
- $o \square Netherlands$
- -∏APAC
- o∏China
- o∏Japan
- o∏India
- o∏South Korea
- o∏Australia
- -□Latin America
- o∏Brazil
- o∏Mexico
- o∏Argentina
- o∏Colombia
- -□Middle East & Africa
- o∏Turkey
- o∏Suadi Arabia
- o∏South Africa
- o∏UAE

#### VENDOR LANDSCAPE

The global IVD reagents market is highly competitive and dynamic within the broader medical diagnostics industry. As healthcare systems increasingly rely on early disease detection, personalized medicine, and point-of-care testing, the demand for reliable and innovative IVD reagents has surged. This demand has led to intensified competition among global players, characterized by innovation, strategic alliances, aggressive market expansion, and pricing pressure. Furthermore, as consumer demand for convenience grows, companies in the IVD reagents market will compete to develop user-friendly, self-testing kits that offer lab-quality results at home. Companies will increasingly focus on targeted diagnostics for specific populations, diseases, or genetic profiles, creating competition in highly specialized niches. Emerging technologies like biosensors, nanotechnology, and lab-on-a-chip platforms will be central to next-gen reagent development and will define future competitive advantage.

The global IVD reagents market is fiercely competitive, shaped by constant innovation, evolving healthcare needs, and emerging technologies. Major players are leveraging product development, global expansion, strategic collaborations, and digital integration to strengthen their market position. However, this rapidly evolving landscape also presents challenges such as regulatory compliance, cost pressures, and technological disruptions. Looking ahead, companies that prioritize agility, innovation, and localized strategies will be best positioned to lead and thrive in the future of diagnostics.

Abbott, Danaher, F. Hoffmann-La Roche, Siemens Healthineers, and Thermo Fisher Scientific are among the key players shaping the global in vitro diagnostics (IVD) reagents market. Abbott stands out as a global leader in this space, offering a comprehensive portfolio of reagent-based solutions across its core laboratory, molecular, point-of-care, and rapid diagnostics segments. Leveraging advanced platforms such as ARCHITECT, Alinity, and ID NOW, Abbott delivers high-throughput and rapid diagnostic capabilities in areas including immunoassays, clinical chemistry, infectious disease detection, and cardiac biomarkers. Its extensive global footprint, strong R&D investments, and established presence in both mature and emerging markets firmly position Abbott as a dominant force in the IVD reagents market.

The report considers the present scenario of the global IVD reagents market and its market dynamics for 2025?2030. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the industry. It also profiles and analyzes leading companies and several other prominent companies operating in the industry.

**Key Company Profiles** 

Scotts International, EU Vat number: PL 6772247784

- $-\square Abbott$
- -□Danaher
- -∏F. Hoffmann La-Roche
- -□Siemens Healthineers
- -□Thermo Fisher Scientific

#### Other Prominent Vendors

- Atomo Diagnostics
- -∏Accelerate Diagnostics
- Agilent Technologies
- -[]altona Diagnostics
- Amoy Diagnostics
- -∏ARKRAY
- $\hbox{-} \square AccuBioTech$
- —The Binding Site Group
- -∏BD
- -□Bio-Rad Laboratories
- -□BIOMERIEUX
- -□bioLytical Laboratories
- -□Biocartis
- -[]Biocept
- -∏Biomerica
- -□Bioway Biological Technology
- -□Boule Diagnostics
- -[Cupid
- Chembio Diagnostics
- -□CPC Diagnostics
- - $\square$ CPM Scientifica
- - $\square$ DIALAB GmbH
- DiaSorin S.p.A.
- -[Diagon
- -∏EDAN Instruments
- -∏Illumina
- Merck KGaA
- -□MP Biomedicals
- -□OraSure Technologies
- -□QIAGEN
- $\square Quidel Or tho$

## **KEY QUESTIONS ANSWERED:**

- 1. How big is the global IVD reagents market?
- 2. What is the growth rate of the global IVD reagents market?
- 3. Which region dominates the global IVD reagents market share?
- $4.\square\mbox{What}$  are the significant trends in the IVD reagents market?
- 5. Who are the key players in the global IVD reagents market?

## Scotts International. EU Vat number: PL 6772247784

#### **Table of Contents:**

- 1. ☐SCOPE & COVERAGE
- 1.1. MARKET DEFINITION
- 1.1.1. □INCLUSIONS
- $1.1.2. \square EXCLUSIONS$
- 1.1.3. MARKET ESTIMATION CAVEATS
- 1.1.4. MARKET SEGMENTATION COVERAGE & DEFINITIONS
- 1.1.5. BY REAGENT TYPE
- 1.1.6. BY TECHNOLOGY
- 1.1.7. □BY APPLICATION
- 1.1.8. □BY END-USER
- 1.1.9. ☐ REGIONS & COUNTRIES COVERED:
- 1.2. MARKET DERIVATION
- 1.2.1. BASE YEAR
- 2. □PREMIUM INSIGHTS
- 2.1. □OPPORTUNITY POCKETS
- 2.2. □OVERVIEW
- 3. MARKET AT A GLANCE
- 4. INTRODUCTION
- 4.1. □OVERVIEW
- 5. MARKET OPPORTUNITIES & TRENDS
- 5.1. RISING SIGNIFICANCE OF BIOMARKER DISCOVERY & COMPANION DIAGNOSTICS
- 5.2. RISE OF POINT-OF-CARE (POC) TESTING
- 5.3. INCREASING DEMAND FOR CUSTOMIZED DIAGNOSTIC TESTS & PERSONALIZED MEDICINE
- 5.4. EXPANSION OF AI AND AUTOMATION IN DIAGNOSTICS
- 6. ☐ MARKET GROWTH ENABLERS
- 6.1. ☐ GROWING PREVALENCE OF CHRONIC & INFECTIOUS DISEASES
- 6.2. ☐ GROWING AWARENESS & EARLY DISEASE DETECTION
- 6.3. INNOVATIONS IN REAGENT FORMULATIONS
- 6.4. □ EXPANDING HEALTHCARE INFRASTRUCTURE & INVESTMENTS IN R&D
- 7. MARKET RESTRAINTS
- 7.1. ☐ HIGH COST OF ADVANCED DIAGNOSTIC TESTS
- 7.2. SUPPLY CHAIN DISRUPTIONS & RAW MATERIAL SHORTAGES
- 7.3. STRINGENT REGULATORY REQUIREMENTS
- 8. ☐ MARKET LANDSCAPE
- 8.1. ☐ MARKET OVERVIEW
- 8.2. MARKET SIZE & FORECAST
- 8.3. ☐ FIVE FORCES ANALYSIS
- 8.3.1. ☐THREAT OF NEW ENTRANTS
- 8.3.2. BARGAINING POWER OF SUPPLIERS
- 8.3.3. BARGAINING POWER OF BUYERS
- 8.3.4. ☐ THREAT OF SUBSTITUTES
- 8.3.5. □COMPETITIVE RIVALRY
- 9. ☐REAGENT TYPE
- 9.1. MARKET SNAPSHOT & GROWTH ENGINE
- 9.2. MARKET OVERVIEW
- 9.3. ☐ IMMUNOCHEMICAL REAGENTS

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.3.1. MARKET OVERVIEW
- 9.3.2. MARKET SIZE & FORECAST
- 9.3.3. MARKET BY GEOGRAPHY
- 9.4. ☐ BIOCHEMICAL REAGENTS
- 9.4.1. MARKET OVERVIEW
- 9.4.2. MARKET SIZE & FORECAST
- 9.4.3. MARKET BY GEOGRAPHY
- 9.5. CHEMICAL REAGENTS
- 9.5.1. MARKET OVERVIEW
- 9.5.2. MARKET SIZE & FORECAST
- 9.5.3. MARKET BY GEOGRAPHY
- 10. □TECHNOLOGY
- 10.1. MARKET SNAPSHOT & GROWTH ENGINE
- 10.2. MARKET OVERVIEW
- 10.3. IMMUNOASSAY & CLINICAL CHEMISTRY
- 10.3.1. MARKET OVERVIEW
- 10.3.2. MARKET SIZE & FORECAST
- 10.3.3. MARKET BY GEOGRAPHY
- 10.4. MOLECULAR DIAGNOSTICS
- 10.4.1. MARKET OVERVIEW
- 10.4.2. MARKET SIZE & FORECAST
- 10.4.3. MARKET BY GEOGRAPHY
- 10.5. ☐ HEMATOLOGY
- 10.5.1. MARKET OVERVIEW
- 10.5.2. MARKET SIZE & FORECAST
- 10.5.3. MARKET BY GEOGRAPHY
- 10.6. MICROBIOLOGY & CYTOLOGY
- 10.6.1. MARKET OVERVIEW
- 10.6.2. MARKET SIZE & FORECAST
- 10.6.3. MARKET BY GEOGRAPHY
- 10.7. □OTHERS
- 10.7.1. MARKET OVERVIEW
- 10.7.2. MARKET SIZE & FORECAST
- 10.7.3. MARKET BY GEOGRAPHY
- 11. □APPLICATION
- 11.1. MARKET SNAPSHOT & GROWTH ENGINE
- 11.2. MARKET OVERVIEW
- 11.3. INFECTIOUS DISEASES
- 11.3.1. MARKET OVERVIEW
- 11.3.2. ☐ MARKET SIZE & FORECAST
- 11.3.3. MARKET BY GEOGRAPHY
- 11.4. □DIABETES
- 11.4.2. MARKET SIZE & FORECAST
- 11.4.3. MARKET BY GEOGRAPHY
- 11.5. CARDIOLOGY
- 11.5.1. MARKET OVERVIEW

- 11.5.2. MARKET SIZE & FORECAST
- 11.5.3. MARKET BY GEOGRAPHY
- 11.6. □ONCOLOGY
- 11.6.1. MARKET OVERVIEW
- 11.6.2. MARKET SIZE & FORECAST
- 11.6.3. MARKET BY GEOGRAPHY
- 11.7. AUTOIMMUNE DISEASE
- 11.7.1. MARKET OVERVIEW
- 11.7.2. MARKET SIZE & FORECAST
- 11.7.3. MARKET BY GEOGRAPHY
- 11.8. □OTHERS
- 11.8.1. ☐ MARKET OVERVIEW
- 11.8.2. MARKET SIZE & FORECAST
- 11.8.3. MARKET BY GEOGRAPHY
- 12. □END-USERS
- 12.1. MARKET SNAPSHOT & GROWTH ENGINE
- 12.2. MARKET OVERVIEW
- 12.3. ☐STANDARD REFERENCE LABS
- 12.3.1. MARKET OVERVIEW
- 12.3.2. MARKET SIZE & FORECAST
- 12.3.3. MARKET BY GEOGRAPHY
- 12.4. HOSPITAL-AFFILIATED LABS
- 12.4.1. MARKET OVERVIEW
- 12.4.2. MARKET SIZE & FORECAST
- 12.4.3. MARKET BY GEOGRAPHY
- 12.5. □CLINICS
- 12.5.1. MARKET OVERVIEW
- 12.5.2. MARKET SIZE & FORECAST
- 12.5.3. MARKET BY GEOGRAPHY
- 12.6. □OTHERS
- 12.6.1. MARKET OVERVIEW
- 12.6.2. MARKET SIZE & FORECAST
- 13. □GEOGRAPHY
- 13.1. MARKET SNAPSHOT & GROWTH ENGINE
- 13.2. ☐GEOGRAPHIC OVERVIEW
- 14. NORTH AMERICA
- 14.1. MARKET OVERVIEW
- 14.2. MARKET SIZE & FORECAST
- 14.2.1. ☐ REAGENT TYPE
- 14.2.2. TECHNOLOGY
- 14.2.3. □ APPLICATION
- 14.2.4.∏END-USER
- 14.3. KEY COUNTRIES
- 14.3.1. US: MARKET SIZE & FORECAST
- 14.3.2. ☐ CANADA: MARKET SIZE & FORECAST
- 15. EUROPE

- 15.1. MARKET OVERVIEW
- 15.2. MARKET SIZE & FORECAST
- 15.2.1. ☐ REAGENT TYPE
- 15.2.2. ☐TECHNOLOGY
- 15.2.3. □APPLICATION
- 15.2.4. ☐ END-USER
- 15.3. KEY COUNTRIES
- 15.3.1. GERMANY: MARKET SIZE & FORECAST
- 15.3.2. ☐ FRANCE: MARKET SIZE & FORECAST
- 15.3.3. RUSSIA: MARKET SIZE & FORECAST
- 15.3.4. ☐ SPAIN: MARKET SIZE & FORECAST
- 15.3.5. ∏ITALY: MARKET SIZE & FORECAST
- 15.3.6. UK: MARKET SIZE & FORECAST
- 15.3.7. NETHERLANDS: MARKET SIZE & FORECAST
- 16. □APAC
- 16.1. MARKET OVERVIEW
- 16.2. MARKET SIZE & FORECAST
- 16.2.1. ☐ REAGENT TYPE
- 16.2.2. TECHNOLOGY
- 16.2.3. □APPLICATION
- 16.2.4. END-USER
- 16.3. KEY COUNTRIES
- 16.3.1. CHINA: MARKET SIZE & FORECAST
- 16.3.2. □JAPAN: MARKET SIZE & FORECAST
- 16.3.3. ☐INDIA: MARKET SIZE & FORECAST
- 16.3.4. SOUTH KOREA: MARKET SIZE & FORECAST
- 16.3.5. □ AUSTRALIA: MARKET SIZE & FORECAST
- 17. LATIN AMERICA
- 17.1. MARKET OVERVIEW
- 17.2. MARKET SIZE & FORECAST
- 17.2.1. REAGENT TYPE
- 17.2.2. □TECHNOLOGY
- 17.2.3. □APPLICATION
- 17.2.4. □ END-USER
- 17.3. KEY COUNTRIES
- 17.3.1. BRAZIL: MARKET SIZE & FORECAST
- 17.3.2. MEXICO: MARKET SIZE & FORECAST
- 17.3.3. □ARGENTINA: MARKET SIZE & FORECAST
- 17.3.4. COLOMBIA: MARKET SIZE & FORECAST
- 18. MIDDLE EAST & AFRICA
- 18.1. MARKET OVERVIEW
- 18.2. MARKET SIZE & FORECAST
- 18.2.1. REAGENT TYPE
- 18.2.2. TECHNOLOGY
- 18.2.3. □ APPLICATION
- 18.2.4. END-USER
- 18.3. KEY COUNTRIES

- 18.3.1. ☐TURKEY: MARKET SIZE & FORECAST
- 18.3.2. SAUDI ARABIA: MARKET SIZE & FORECAST
- 18.3.3. SOUTH AFRICA: MARKET SIZE & FORECAST
- 18.3.4. UAE: MARKET SIZE & FORECAST
- 19. COMPETITIVE LANDSCAPE
- 19.1. COMPETITION OVERVIEW
- 19.2. KEY VENDOR ANALYSIS
- 19.2.1. □ ABBOTT
- 19.2.2. □DANAHER
- 19.2.3. F. HOFFMANN-LA ROCHE
- 19.2.4. 

  ∏SIEMENS HEALTHINEERS
- 19.2.5. THERMO FISHER SCIENTIFIC
- 20. □KEY COMPANY PROFILES
- 20.1. □ABBOTT
- 20.1.1. BUSINESS OVERVIEW
- 20.1.1. □PRODUCT OFFERINGS
- 20.1.2. □KEY STRATEGIES
- 20.1.3. □KEY STRENGTHS
- 20.1.4. ☐ KEY OPPORTUNITIES
- 20.2. □DANAHER
- 20.2.1. BUSINESS OVERVIEW
- 20.2.2. □PRODUCT OFFERINGS
- 20.2.3. □KEY STRATEGIES
- 20.2.4. KEY STRENGTHS
- 20.2.5. ☐ KEY OPPORTUNITIES
- 20.3. ☐F. HOFFMANN-LA ROCHE
- 20.3.1. BUSINESS OVERVIEW
- 20.3.2. ☐ PRODUCT OFFERINGS
- 20.3.3. KEY STRATEGIES
- 20.3.4. 

  KEY STRENGTHS
- 20.4. 

  ∏SIEMENS HEALTHINEERS
- 20.4.1. □BUSINESS OVERVIEW
- 20.4.2. □PRODUCT OFFERINGS
- 20.4.3. ☐KEY STRATEGIES
- 20.4.4. KEY STRENGTHS
- 20.4.5. □KEY OPPORTUNITIES
- 20.5. THERMO FISHER SCIENTIFIC
- 20.5.1. BUSINESS OVERVIEW
- 20.5.2. ☐ PRODUCT OFFERINGS
- 20.5.3. KEY STRATEGIES
- 20.5.4. KEY STRENGTHS
- 21. □OTHER PROMINENT VENDORS
- 21.1. ☐ ATOMO DIAGNOSTICS
- 21.1.1. BUSINESS OVERVIEW
- 21.1.2. ☐ PRODUCT OFFERINGS

- 21.2. □ACCELERATE DIAGNOSTICS
- 21.2.1. BUSINESS OVERVIEW
- 21.2.2. □PRODUCT OFFERINGS
- 21.3. □ AGILENT TECHNOLOGIES
- 21.3.1. BUSINESS OVERVIEW
- 21.3.2. PRODUCT OFFERINGS
- 21.4. ALTONA DIAGNOSTICS
- 21.4.1. BUSINESS OVERVIEW
- 21.4.2. □PRODUCT OFFERINGS
- 21.5. ∏AMOY DIAGNOSTICS
- 21.5.1. ☐ BUSINESS OVERVIEW
- 21.5.2. PRODUCT OFFERINGS
- 21.6. □ARKRAY
- 21.6.1. BUSINESS OVERVIEW
- 21.6.2. PRODUCT OFFERINGS
- 21.7. □ACCUBIOTECH
- 21.7.1. BUSINESS OVERVIEW
- 21.7.2. □PRODUCT OFFERINGS
- 21.8.□BD
- 21.8.1. ☐ BUSINESS OVERVIEW
- 21.8.2. □PRODUCT OFFERINGS
- 21.9. BIO-RAD LABORATORIES
- 21.9.1. ☐ BUSINESS OVERVIEW
- 21.9.2. □PRODUCT OFFERINGS
- 21.10. ☐BIOMERIEUX
- 21.10.1. ☐BUSINESS OVERVIEW
- 21.10.2. ☐ PRODUCT OFFERINGS
- 21.11. ☐ BIOLYTICAL LABORATORIES
- 21.11.1. BUSINESS OVERVIEW
- 21.11.2. □PRODUCT OFFERINGS
- 21.12. BIOCARTIS
- 21.12.1. ☐ BUSINESS OVERVIEW
- 21.12.2. □PRODUCT OFFERINGS
- 21.13.∏BIOCEPT
- 21.13.1. BUSINESS OVERVIEW
- 21.13.2. □PRODUCT OFFERINGS
- 21.14. ☐BIOMERICA
- 21.14.1. BUSINESS OVERVIEW
- 21.14.2. □PRODUCT OFFERINGS
- 21.15. ☐BIOWAY BIOLOGICAL TECHNOLOGY
- 21.15.1. BUSINESS OVERVIEW
- 21.15.2. PRODUCT OFFERINGS
- 21.16. BOULE
- 21.16.1. BUSINESS OVERVIEW
- 21.16.2. PRODUCT OFFERINGS
- 21.17. CUPID
- 21.17.1. BUSINESS OVERVIEW

- 21.17.2. PRODUCT OFFERINGS
- 21.18. CHEMBIO DIAGNOSTICS
- 21.18.1. BUSINESS OVERVIEW
- 21.18.2. □PRODUCT OFFERINGS
- 21.19. □CPC DIAGNOSTICS
- 21.19.1. BUSINESS OVERVIEW
- 21.19.2. □PRODUCT OFFERINGS
- 21.20. □CPM SCIENTIFICA
- 21.20.1. BUSINESS OVERVIEW
- 21.20.2. □PRODUCT OFFERINGS
- 21.21. □DIALAB GMBH
- 21.21.1. □BUSINESS OVERVIEW
- 21.21.2. □PRODUCT OFFERINGS
- 21.22. DIASORIN S. P.A.
- 21.22.1. BUSINESS OVERVIEW
- 21.22.2. □PRODUCT OFFERINGS
- 21.23. DIAGON
- 21.23.1. BUSINESS OVERVIEW
- 21.23.2. ☐ PRODUCT OFFERINGS
- 21.24. □EDAN INSTRUMENTS
- 21.24.1. BUSINESS OVERVIEW
- 21.24.2. ☐ PRODUCT OFFERINGS
- 21.25.∏ILLUMINA
- 21.25.1. BUSINESS OVERVIEW
- 21.25.2. □PRODUCT OFFERINGS
- 21.26. MERCK KGAA
- 21.26.1. BUSINESS OVERVIEW
- 21.26.2. □PRODUCT OFFERINGS
- 21.27. MP BIOMEDICALS
- 21.27.1. BUSINESS OVERVIEW
- 21.27.2. PRODUCT OFFERINGS
- 21.28. □ORASURE TECHNOLOGIES
- 21.28.1. □BUSINESS OVERVIEW
- 21.28.2. □PRODUCT OFFERINGS
- 21.29. □QIAGEN
- 21.29.1. BUSINESS OVERVIEW
- 21.29.2. ☐ PRODUCT OFFERINGS
- 21.30. QUIDELORTHO
- 21.30.1. BUSINESS OVERVIEW
- 21.30.2. ☐ PRODUCT OFFERINGS
- 22. REPORT SUMMARY
- 22.1. KEY TAKEAWAYS
- 22.2. □STRATEGIC RECOMMENDATIONS
- 23. □QUANTITATIVE SUMMARY
- 23.1. MARKET BY GEOGRAPHY
- 23.1.1. IMMUNOCHEMICAL REAGENTS
- 23.1.2. BIOCHEMICAL REAGENTS

- 23.1.3. CHEMICAL REAGENTS
- 23.1.4. IMMUNOASSAY & CLINICAL CHEMISTRY
- 23.1.5. MOLECULAR DIAGNOSTICS
- 23.1.6. HEMATOLOGY
- 23.1.7. MICROBIOLOGY & CYTOLOGY
- 23.1.8. OTHER TECHNOLOGY
- 23.1.9. INFECTIOUS DISEASES
- 23.1.10. DIABETES
- 23.1.11. CARDIOLOGY
- 23.1.12. ONCOLOGY
- 23.1.13. □AUTOIMMUNE DISEASES
- 23.1.14. ☐ OTHER APPLICATION
- 23.1.15. ☐STANDARD REFERENCE LABS
- 23.1.16. HOSPITAL-AFFILIATED LABS
- 23.1.17. CLINICS
- 23.1.18. □OTHER END-USER
- 24. □APPENDIX
- 24.1. RESEARCH METHODOLOGY
- 24.2. RESEARCH PROCESS
- 24.3. REPORT ASSUMPTIONS & CAVEATS
- 24.3.1. KEY CAVEATS
- 24.3.2. □CURRENCY CONVERSION
- 24.4. ABBREVIATIONS



☐ - Print this form

To place an Order with Scotts International:

☐ - Complete the relevant blank fields and sign

# In-vitro Diagnostics (IVD) Reagents Market - Global Outlook & Forecast 2025-2030

Market Report | 2025-05-13 | 354 pages | Arizton Advisory & Intelligence

Select license	License			Price
	Single User License			\$4799.00
	Team License			\$4999.00
	Enterprisewide			\$5999.00
				VAT
				Total
** VAT will be added a			companies who are unable to pro	
** VAT will be added a		Phone*		
** VAT will be added a		ies, individuals and EU based		
		Phone*		
** VAT will be added a Email* First Name* lob title*		Phone*	companies who are unable to pro	
** VAT will be added a  Email*  First Name*  lob title*  Company Name*		Phone*  Last Name*	companies who are unable to pro	
** VAT will be added a  Email*  First Name*  Job title*  Company Name*  Address*		Phone*  Last Name*  EU Vat / Tax ID	companies who are unable to pro	
** VAT will be added a  Email*  First Name*  Job title*  Company Name*  Address*		Phone*  Last Name*  EU Vat / Tax ID /	companies who are unable to pro	
□** VAT will be added a Email* First Name*		Phone*  Last Name*  EU Vat / Tax ID /  City*  Country*	/ NIP number*	

Scotts International. EU Vat number: PL 6772247784